



EUROPEAN
HEMATOLOGY
ASSOCIATION



EHA-SWG SCIENTIFIC MEETING

Multiple Myeloma

Dates: September 5-7, 2014

Location: Barcelona, Spain

Organized by:

EHA & SWG Multiple Myeloma

Chair:

Gareth Morgan

Topics:

- Genome wide studies
- Molecular diagnostics
- GWAS analyses
- Imaging
- MRD monitoring
- Myeloma stem cells
- Targeted treatment strategies
- Clinical trial portfolio
- Biobanking
- Guidelines

Early registration deadline: August 1, 2014

EHA-SWG Scientific Meeting

Multiple Myeloma

Venue: Hotel Avenida Palace, Barcelona

Day 1, Friday September 5, 2014 - The molecular of myeloma

Time	Title	Speaker
13:00-13:55	Registration	
14:00-14:15	WELCOME & INTRODUCTORY REMARKS	G Morgan & P Sonneveld
14:15-16:00	Genome wide analysis of myeloma	Chairs: G Morgan/ N Munshi
14:15-14:30	Mutational landscape of myelma and its clinical use	N Munshi
14:30-14:45	Genome wide mapping analysis of myeloma	N Weinhold
14:45-15:00	Methylation analysis and its significance for myeloma initiation and prognosis	M Kaiser
15:00-15:15	Tumour diversity and prognosis in myeloma	G Morgan
15:15-16:00	Discussion and strategy going forward	
15:45-16:15	Coffee Break	
16:15-18:00	Molecular diagnostic approaches for myeloma	Chairs: H Avet-Loisseau/M Kaiser
16:15-16:30	What infrastructure is needed to run a risk adapted study	M Cavo
16:30-16:45	The future of FISH for the diagnosis of presenting myeloma	H Avet-Loisseau
16:45-17:00	Using GEP as a diagnostic tool in the clinical arena	P Sonneveld
17:00-17:15	New molecular diagnostic strategies for presenting myeloma	M Kaiser
17:15-18:00	Discussion and strategy going forward	
18:00-18:15	WRAP UP DAY 1	Chairs and Speakers
18:15-19:15	Welcome Reception	

Day 2, Saturday September 6, 2014 - Risk stratification, molecular monitoring and targeted treatment of myeloma

Time	Title	Speaker
09:00-10:15	GWAS analyses of myeloma	Chairs: H Goldschmidt/ G Morgan
	Aetiology of myeloma	
09:00-09:15	The aetiology of myeloma genetics versus environment	G Morgan
09:15-09:30	Inherited variation – risk and outcome of myeloma	H Goldschmidt
09:30-09:45	Expression quantitative trait loci (eQTL) analysis	D Johnson
09:45-10:15	Discussion and strategy going forward	
10:15-11:15	Imaging analyses of myeloma	Chairs: E Terpos/ M Cavo
10:15-10:30	Imaging of bone lesions in the clinic	E Terpos
10:30-10:45	Novel approaches for imaging of bone in myeloma	E Zamagni
10:45-11:00	Focal lesions and their impact on biology and prognosis	J Hillengass
11:00-11:15	Discussion and strategy going forward	
11:15-11:45	Coffee Break	
11:45-13:00	MRD monitoring directed treatment	Chair: B Paiva
11:45-12:00	Response definitions and MRD as a clinical end point	S Zweegman
12:00-12:15	Flow based MRD detection	B Paiva
12:15-12:30	PCR based MRD detection	N Munshi/A Palumbo
12:30-12:45	Discussion and strategy going forward	
12:45-13:00	WRAP-UP SESSION DAY 2/1	
13:00-14:30	Lunch	
14:30-15:45	Multiple Myeloma initiating cells	Chairs: H Lokhorst/ HE Johnsen
14:30-14:45	The European MSCNET conclusions and a model for future collaborations	HE Johnsen
14:45-15:00	Mouse models of myeloma	H Lokhorst
15:00-15:15	New mouse models for modeling disease outcomes	A Beilhack
15:15-15:30	Single cell analyses and intraclonal heterogeneity	L Melchor
15:30-15:45	Discussion and future strategies	
15:45-16:15	Coffee Break	
16:15-17:45	Targeting treatment strategies	Chairs: P Sonneveld/ F Prosper
16:15-16:30	Targeting RAS/MYC – the myeloma defining mutations	F Davies

Time	Title	Speaker
16:30-16:45	Targeting the epigenome as a therapeutic strategy in myeloma	F Prosper
16:45-17:00	Targeting protein homeostasis the Achilles heel of myeloma	H Einsele
17:00-17:35	Discussion and strategy going forward	
17:35-17:45	WRAP-UP SESSION DAY 2/2	

Day 3, Sunday September 7, 2014 - Trials and tribulations

Time	Title	Speaker
09:00-10:20	Clinical trial portfolio	Chairs: A Palumbo/ P Moreau
09:00-09:10	Current EMN clinical trials & country specific studies	A Palumbo
09:10-09:20	Can we cure myeloma – impacts for trial design	P Moreau
09:20-09:30	Risk stratified trials – their benefits and obstacles	G Morgan
09:30-09:40	Trials for the frail elderly patient with myeloma	H Ludwig
09:40-09:50	Trials for the younger fitter patient with myeloma	M Dimopoulos
09:50-10:20	Discussion and future strategies	
10:20-10:40	Coffee Break	
10:40-11:20	Biobanking in clinical trials	Chairs: M Cavo/ S Zweegman
10:40-10:55	The current status of biobanking in European trials	S Zweegman
10:55-11:10	Quality control of stored samples	D Johnson
11:10-11:30	Future strategies and discussion	
11:30-12:40	Guidelines	Chair: M Engelhardt
11:30-11:50	Current portfolio of clinical guidelines	M Engelhardt
11:50-12:10	Strategies for developing new drugs and European scientific guidance	P Demolis
12:10-12:40	Discussion and strategies going forward	
12:40-13:00	Concluding remarks	
13:00-14:30	Lunch and Departures	